These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9762353)

  • 1. Towards the structure-based design of oligonucleotide therapeutics.
    Egli M
    Adv Enzyme Regul; 1998; 38():181-203. PubMed ID: 9762353
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and structural analysis of [4.3.0]-bicyclothymidine.
    Stauffiger A; Leumann CJ
    Nucleic Acids Symp Ser (Oxf); 2008; (52):267-8. PubMed ID: 18776356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational preorganization, hydration, and nucleic acid duplex stability.
    Egli M
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):123-8. PubMed ID: 9593050
    [No Abstract]   [Full Text] [Related]  

  • 4. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
    Orum H; Wengel J
    Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2'-O-ribonucleic acid modifications.
    Egli M; Minasov G; Tereshko V; Pallan PS; Teplova M; Inamati GB; Lesnik EA; Owens SR; Ross BS; Prakash TP; Manoharan M
    Biochemistry; 2005 Jun; 44(25):9045-57. PubMed ID: 15966728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating RNA bulges: cleavage of RNA in RNA/DNA duplexes by metal ion catalysis.
    Hüsken D; Goodall G; Blommers MJ; Jahnke W; Hall J; Häner R; Moser HE
    Biochemistry; 1996 Dec; 35(51):16591-600. PubMed ID: 8987994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing chemically modified oligonucleotides for targeted gene silencing.
    Deleavey GF; Damha MJ
    Chem Biol; 2012 Aug; 19(8):937-54. PubMed ID: 22921062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in antisense therapeutics.
    Agrawal S; Iyer RP
    Pharmacol Ther; 1997; 76(1-3):151-60. PubMed ID: 9535177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency.
    Mitsuoka Y; Yamamoto T; Kugimiya A; Waki R; Wada F; Tahara S; Sawamura M; Noda M; Fujimura Y; Kato Y; Hari Y; Obika S
    J Org Chem; 2017 Jan; 82(1):12-24. PubMed ID: 27936689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp.
    Wilds CJ; Maier MA; Tereshko V; Manoharan M; Egli M
    Angew Chem Int Ed Engl; 2002 Jan; 41(1):115-7. PubMed ID: 12491456
    [No Abstract]   [Full Text] [Related]  

  • 12. Conformationally controlled high-affinity targeting of RNA or DNA by novel 2'-amino-DNA/LNA mixmers and pyrenyl-functionalized 2'-amino-DNA.
    Kalra N; Babu BR; Parmar VS; Wengel J
    Org Biomol Chem; 2004 Oct; 2(20):2885-7. PubMed ID: 15480448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in locked nucleic acid research].
    Li SM; Xu X; Liang HP; Li L
    Sheng Li Ke Xue Jin Zhan; 2003 Oct; 34(4):319-23. PubMed ID: 14992013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antisense strategy--new trends].
    Koziołkiewicz M
    Postepy Biochem; 1998; 44(2):125-35. PubMed ID: 9770236
    [No Abstract]   [Full Text] [Related]  

  • 15. Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides.
    Egli M; Pallan PS
    Annu Rev Biophys Biomol Struct; 2007; 36():281-305. PubMed ID: 17288535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
    Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058
    [No Abstract]   [Full Text] [Related]  

  • 18. LNA and alpha-L-LNA: towards therapeutic applications.
    Wengel J; Vester B; Lundberg LB; Douthwaite S; Sørensen MD; Babu BR; Gait MJ; Arzumanov A; Petersen M; Nielsen JT
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):601-4. PubMed ID: 14565236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes.
    Crooke ST; Lemonidis KM; Neilson L; Griffey R; Lesnik EA; Monia BP
    Biochem J; 1995 Dec; 312 ( Pt 2)(Pt 2):599-608. PubMed ID: 8526876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.